Ascendis Pharma A/S
ASND
주식 순위
#1499
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
주가
$234.15
마지막 동기화: 2026-10-20
시가총액
$14.61B
변동 (1일)
1.82%
변동 (1년)
16.73%
국가
DK
거래 Ascendis Pharma A/S (ASND)
카테고리
Healthcare
Ascendis Pharma A/S (ASND)의 매출
Jun 2026 기준 매출 TTM: $1.25B
Ascendis Pharma A/S의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.25B입니다. 2024년에 회사는 $378.39M의 수익을 올렸으며 이는 2023년의 $294.85M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Ascendis Pharma A/S의 수익 기록 (2012 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.25B | 54.10% |
| 2025 | $811.56M | 114.48% |
| 2024 | $378.39M | 28.34% |
| 2023 | $294.85M | 437.13% |
| 2022 | $54.89M | 520.63% |
| 2021 | $8.84M | 4.45% |
| 2020 | $8.47M | -43.57% |
| 2019 | $15.01M | 23.42% |
| 2018 | $12.16M | 562.32% |
| 2017 | $1.84M | -62.12% |
| 2016 | $4.85M | -45.02% |
| 2015 | $8.81M | -47.90% |
| 2014 | $16.92M | -39.71% |
| 2013 | $28.06M | 36.53% |
| 2012 | $20.56M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 909.42% |
US
|
|
| $2.23B | 78.15% |
US
|
|
| $15.74B | 1,158.89% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 381.45% |
NL
|
